Cargando…

Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins

BACKGROUND: Intravenous immunoglobulin (IVIg) is an effective treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). In most patients, the optimal IVIg dose and regime is unknown. Polyvalent immunoglobulin (Ig) G form idiotypic/anti-idiotypic antibody pairs in serum and IVIg preparat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ritter, Christian, Bobylev, Ilja, Lehmann, Helmar C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535537/ https://www.ncbi.nlm.nih.gov/pubmed/26268846 http://dx.doi.org/10.1186/s12974-015-0361-1

Ejemplares similares

Loss of Schwann cell plasticity in chronic inflammatory demyelinating polyneuropathy (CIDP)
por: Joshi, Abhijeet R., et al.
Publicado: (2016)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
por: Blackhouse, Gord, et al.
Publicado: (2010)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
por: Alsolaihim, Alanood, et al.
Publicado: (2020)

Comparison of diabetes patients with “demyelinating” diabetic sensorimotor polyneuropathy to those diagnosed with CIDP
por: Dunnigan, Samantha K, et al.
Publicado: (2013)

Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)
por: Querol, Luis, et al.
Publicado: (2020)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Diabetes Mellitus: A Diagnostic Dilemma
por: Valentin, Marcos, et al.
Publicado: (2022)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Overview, Treatment, and a Case Study
por: Ponnala, Madhusudhan, et al.
Publicado: (2023)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): An Uncommon Manifestation of Systemic Lupus Erythematosus (SLE)
por: Abraham, Hrudya, et al.
Publicado: (2017)

Conductive hearing loss in chronic inflammatory demyelinating polyneuropathy (CIDP): A case report
por: Fadel, Mark A., et al.
Publicado: (2018)

Chronic inflammatory demyelinating polyneuropathy‐like neuropathy in IgG4‐related disease
por: Wang, Cong‐Cong, et al.
Publicado: (2021)

Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
por: Mahdi-Rogers, Mohamed, et al.
Publicado: (2010)

Modified recombinant human IgG1‐Fc is superior to natural intravenous immunoglobulin at inhibiting immune‐mediated demyelination
por: Baksmeier, Christine, et al.
Publicado: (2021)

Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post‐hoc analysis of the immunoglobulin overtreatment in CIDP trial
por: van Veen, Robin, et al.
Publicado: (2022)

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Khoo, Anthony, et al.
Publicado: (2019)

Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy
por: Seino, Yusuke, et al.
Publicado: (2018)

The antiinflammatory activity of IgG: the intravenous IgG paradox
por: Nimmerjahn, Falk, et al.
Publicado: (2007)

Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: A systematic review and meta‐analysis
por: Hu, Wenyu, et al.
Publicado: (2018)

Demyelinating Neuropathy with Markedly Elevated Serum IgG4 Levels and Anti-Contactin 1 IgG4 Antibody
por: Fukushima, Taiki, et al.
Publicado: (2022)

Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement
por: Weide, Rudolf, et al.
Publicado: (2020)

Reference ranges for serum immunoglobulin (IgG, IgA, and IgM) and IgG subclass levels in healthy children
por: BAYRAM, Rumeysa Olcay, et al.
Publicado: (2019)

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
por: Cornblath, David R., et al.
Publicado: (2023)

A case of CIDP concurrent with MGUS IgG kappa responsive to autologous stem cell transplantation
por: Colucci, Giuseppe, et al.
Publicado: (2020)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype
por: Cortese, Andrea, et al.
Publicado: (2019)

Retrospective correlation analysis of plasma Immunoglobulin G and clinical performance in CIDP
por: Markvardsen, Lars Kjøbsted, et al.
Publicado: (2019)

A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
por: Mallick, Rajiv, et al.
Publicado: (2023)

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US
por: Guptill, Jeffrey T, et al.
Publicado: (2019)

Subclasses of allergen-specific IgG: Serum IgG2 and IgG3 levels are not predicted by IgG1/IgG4 levels
por: MacGlashan, Donald, et al.
Publicado: (2021)

Serum Immunoglobulin G (IgG) Subclasses in a Cohort of Systemic Sclerosis Patients
por: Pellicano, Chiara, et al.
Publicado: (2023)

Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study
por: Masanneck, Lars, et al.
Publicado: (2023)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

Thirteen-Valent Pneumococcal Conjugate Vaccine–Induced Immunoglobulin G (IgG) Responses in Serum Associated With Serotype-Specific IgG in the Lung
por: Mitsi, Elena, et al.
Publicado: (2021)

Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report
por: Gil-Perotin, Sara, et al.
Publicado: (2018)

MRI biomarkers of proximal nerve injury in CIDP
por: Lichtenstein, Thorsten, et al.
Publicado: (2017)

Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
por: Kohle, Felix, et al.
Publicado: (2023)

Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy
por: Markvardsen, Lars K., et al.
Publicado: (2023)

Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective
por: Cocito, Dario, et al.
Publicado: (2023)

Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions
por: Gingele, Stefan, et al.
Publicado: (2021)

Comparison of enzyme-linked immunosorbent assay and Fassisi(®) bovine immunoglobulin G (IgG) immunoassay for quantification of bovine IgG in neonatal calf serum
por: Hampe, Marian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l6l612ts5a7frv3um4l5p9k24q